MMR

Nasdaq Reverses Losses Amid Nvidia Fanfare

The VIX reclaimed 17 earlier due to geopolitical unrest

Digital Content Manager
Nov 19, 2024 at 11:39 AM
facebook X logo linkedin


Stocks are attempting to walk back this morning's losses tied to escalating tensions between Russia and Ukraine. The S&P 500 Index (SPX) is flat this afternoon, and the Nasdaq Composite (IXIC) sports a solid lead after flipping into positive territory thanks to Nvidia's (NVDA) pre-earnings surge. The Dow Jones Industrial Average (DJI) still carries a 172-point loss despite Walmart's (WMT) blowout results, while the Cboe Volatility Index (VIX) -- also known as Wall Street's "fear gauge" -- reclaimed 17 earlier.

Continue reading for more on today's market, including: 

  • Lowe's stock falls on dreary outlook.
  • Analyst: Buy BioNTech stock's recent dip.
  • Plus, Walmart bulls rush in; ALB eyes key level; and Incyte pauses mid-stage trial.

Midday Market Stats November 192024

Options traders are blasting Walmart Inc(NYSE:WMT) stock after the retail giant's better-than-expected third-quarter results and raised guidance. So far today, 121,000 calls and 105,000 puts have traded hands, which is seven times the volume normally seen at this point. The most popular contract is the weekly 11/22 90-strike call, where new positions are being opened. WMT was last seen 4.2% higher to trade at a record high of $87.56. After staging a bounce off its 20-day moving average, the shares now sport a 64.7% year-to-date lead.

WMT 20 Day

Albemarle Corporation (NYSE:ALB) stock is near the top of the SPX today, up 2.7% to trade at $106.88 at last glance. UBS earlier hiked its price objective on ALB to $108 from $102. The shares are still struggling with a newly formed ceiling at the $110 level, which rejected two rallies this month, but are eyeing their fourth gain in the past five sessions. For 2024, ALB carries a 25.6% deficit.

Down 11.6% to trade at $68.06 at last check, Incyte Corp (NASDAQ:INCY) stock is leading the SPX lower. Today's losses come after the pharmaceutical name paused a mid-stage trial of its experimental drug to treat a chronic skin condition due to safety concerns. Shares are pacing for their biggest single-day percentage drop since April 2018 and sixth loss in the last seven sessions, but still sport a 24.3% year-over-year lead.

 

Follow us on X, Follow us on Twitter

 

Nvidia and its powerful chips are the face of artificial intelligence.

But while everyone’s patting Nvidia on the back for record earnings…

It’s quietly moved on to the next phase of AI it plans to conquer…

Nvidia recently unveiled essential blueprints for this crucial $1 trillion pivot.

Click here now and find out about the three companies Nvidia absolutely needs to succeed in this vital new AI frontier.
 (ad)